Abstract
Oncogenic alterations in RET represent important therapeutic targets in thyroid cancer. We aimed to assess the safety and antitumour activity of pralsetinib, a highly potent, selective RET inhibitor, in patients with RET-altered thyroid cancers. ARROW, a phase 1/2, open-label study done in 13 countries across 71 sites in community and hospital settings, enrolled patients 18 years or older with RET-altered locally advanced or metastatic solid tumours, including RET-mutant medullary thyroid and RET fusion-positive thyroid cancers, and an Eastern Co-operative Oncology Group performance status of 0-2 (later limited to 0-1 in a protocol amendment). Phase 2 primary endpoints assessed for patients who received 400 mg once-daily oral pralsetinib until disease progression, intolerance, withdrawal of consent, or investigator decision, were overall response rate (Response Evaluation Criteria in Solid Tumours version 1.1; masked independent central review) and safety. Tumour response was assessed for patients with RET-mutant medullary thyroid cancer who had received previous cabozantinib or vandetanib, or both, or were ineligible for standard therapy and patients with previously treated RET fusion-positive thyroid cancer; safety was assess...Continue Reading
References
Mar 10, 2001·International Journal of Cancer. Journal International Du Cancer·T SchillingF Raue
Jun 9, 2004·Oncogene·Francesca CarlomagnoMassimo Santoro
Sep 2, 2006·Endocrinology·Raffaele Ciampi, Yuri E Nikiforov
Oct 5, 2006·Cancer·Sanziana RomanJulie Ann Sosa
Dec 13, 2007·The Journal of Clinical Endocrinology and Metabolism·Rossella EliseiAldo Pinchera
Oct 26, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Samuel A WellsMartin J Schlumberger
May 1, 2012·Current Oncology Reports·Suzanne R HaymanVesna D Garovic
May 25, 2012·Clinics·Simona M WagnerLois M Mulligan
Jun 2, 2012·Current Genomics·Taccaliti ABoscaro M
Jul 19, 2012·Histopathology·Margriet M de VriesPaula Soares
Jan 1, 2011·Oncology Letters·Michael StamatakosKonstantinos Kontzoglou
May 28, 2013·Thyroid : Official Journal of the American Thyroid Association·Frauke BentzienF Michael Yakes
Sep 5, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rossella EliseiSteven I Sherman
Apr 29, 2014·Lancet·Marcia S BroseUNKNOWN DECISION investigators
Feb 12, 2015·The New England Journal of Medicine·Martin SchlumbergerSteven I Sherman
Mar 27, 2015·Thyroid : Official Journal of the American Thyroid Association·Samuel A WellsUNKNOWN American Thyroid Association Guidelines Task Force on Medullary Thyroid Carcinoma
Jun 17, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Mehdi TouatJean-Charles Soria
Sep 1, 2013·EJC Supplements : EJC : Official Journal of EORTC, European Organization for Research and Treatment of Cancer ... [et Al.]·Manuela Schmidinger
Sep 30, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Shumei KatoRazelle Kurzrock
Apr 17, 2018·Cancer Discovery·Vivek SubbiahErica K Evans
Nov 24, 2018·Cancer Genetics·Julia Isabelle StaubitzThomas Johannes Musholt
Feb 23, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Vivek SubbiahFunda Meric-Bernstam
Feb 26, 2020·Cancer Discovery·Vivek Subbiah, Gilbert J Cote
Apr 25, 2020·Genes·Massimo SantoroFrancesca Carlomagno
Aug 28, 2020·The New England Journal of Medicine·Lori J WirthMaria E Cabanillas
Jun 13, 2021·The Lancet Oncology·Justin F GainorVivek Subbiah
Citations
Jun 15, 2021·The Lancet. Diabetes & Endocrinology·Joanna Klubo-Gwiezdzinska
Aug 16, 2021·Trends in Cancer·Kyaw Z TheinVivek Subbiah
Jul 23, 2021·Current Opinion in Endocrinology, Diabetes, and Obesity·Tania JaberMimi I Hu
Oct 1, 2021·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Angel W LiuChung-Shien Lee
Sep 9, 2021·Molecular Cancer Therapeutics·Jacob J AdashekVivek Subbiah
Nov 3, 2021·Journal of Managed Care & Specialty Pharmacy·Steve DuffErin Sullivan
Nov 27, 2021·Deutsche medizinische Wochenschrift·Matthias KroissChristine Spitzweg